Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.49 -3.5%	$2.61	$1.78 ▼ $10.14	$53.90M	0.71	268,962 shs	210,492 shs
CADL Candel Therapeutics	$5.03 +3.7%	$5.20	$3.79 ▼ $14.60	$243M	-0.87	1.48 million shs	899,689 shs
CRVS Corvus Pharmaceuticals	$4.21 +2.2%	$3.78	$1.75 ▼ $10.00	$280.86M	0.57	785,908 shs	867,912 shs
LFCR Lifecore Biomedical	$8.23 -1.3%	$6.84	$3.68 ▼ $8.63	$308.79M	0.65	234,503 shs	174,696 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	-3.49%	+8.73%	+9.69%	-45.99%	-64.33%
CADL Candel Therapeutics	+3.71%	+2.24%	-10.18%	-15.46%	-11.91%
CRVS Corvus Pharmaceuticals	+2.18%	+7.12%	+14.71%	+24.56%	+135.20%
LFCR Lifecore Biomedical	-1.32%	+22.65%	+17.57%	+20.15%	+70.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	3.9782 of 5 stars	3.4	1.0	4.8	1.9	2.5	0.6
CADL Candel Therapeutics	2.4542 of 5 stars	3.5	3.0	0.0	2.5	0.8	0.6
CRVS Corvus Pharmaceuticals	2.7902 of 5 stars	3.5	2.0	0.0	2.9	2.5	0.6
LFCR Lifecore Biomedical	1.7996 of 5 stars	1.3	3.0	0.0	3.8	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	855.82% Upside
CADL Candel Therapeutics	3.00	Buy	$21.00	317.50% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	256.29% Upside
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	-2.79% Downside

Current Analyst Ratings Breakdown

Latest ADVM, LFCR, CRVS, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/9/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00
4/17/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $33.00
4/16/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$10.00 ➝ $5.00
4/16/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/11/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	52.02	N/A	N/A	$3.40 per share	0.73
CADL Candel Therapeutics	$120K	2,100.03	N/A	N/A	$1.41 per share	3.57
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.51 per share	N/A
LFCR Lifecore Biomedical	$128.26M	2.38	N/A	N/A	$0.37 per share	22.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	8/12/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$0.98	N/A	N/A	N/A	N/A	-24.04%	-13.90%	8/5/2025 (Estimated)
LFCR Lifecore Biomedical	$12.01M	-$1.45	N/A	N/A	N/A	-35.90%	-551.09%	-13.89%	8/15/2025 (Estimated)

Latest ADVM, LFCR, CRVS, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A
4/3/2025	Q3 2025	LFCR Lifecore Biomedical	-$0.14	-$0.19	-$0.05	-$0.47	$33.23 million	$35.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
CADL Candel Therapeutics	0.01	4.64	4.64
CRVS Corvus Pharmaceuticals	N/A	4.90	4.90
LFCR Lifecore Biomedical	66.36	2.71	1.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
CADL Candel Therapeutics	13.93%
CRVS Corvus Pharmaceuticals	46.64%
LFCR Lifecore Biomedical	83.36%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
CADL Candel Therapeutics	16.60%
CRVS Corvus Pharmaceuticals	28.50%
LFCR Lifecore Biomedical	32.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	48.74 million	Optionable
LFCR Lifecore Biomedical	690	37.03 million	25.10 million	Optionable

ADVM, LFCR, CRVS, and CADL Headlines

Recent News About These Companies

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Position Trimmed by Rhumbline Advisers

June 26 at 3:13 AM | marketbeat.com

Lifecore Signs 10-Year Manufacturing Deal To Support Novel Ophthalmic Therapy

June 18, 2025 | kalkinemedia.comK

Lifecore Biomedical: Inflecting Financials Over Next 3 Years

June 18, 2025 | seekingalpha.com

Lifecore Biomedical signs new 10-year commercial manufacturing and supply agreement

June 17, 2025 | msn.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect

June 17, 2025 | accessnewswire.comA

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer

June 17, 2025 | globenewswire.com

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

June 15, 2025 | accessnewswire.comA

Lifecore Receives Full Payment Early For $17 Mln Equipment Sale

June 14, 2025 | nasdaq.com

Lifecore Biomedical, Inc.: Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

June 12, 2025 | finanznachrichten.de

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation

June 12, 2025 | accessnewswire.comA

Lifecore Biomedical receives accelerated payment of remaining $10M in proceeds from equipment sale

June 12, 2025 | msn.com

Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

June 12, 2025 | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation

June 10, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out

June 8, 2025 | accessnewswire.comA

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation

June 5, 2025 | accessnewswire.comA

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

June 3, 2025 | accessnewswire.comA

Deutsche Bank AG Reduces Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

June 3, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Shareholders to Inquire about Securities Investigation

June 1, 2025 | accessnewswire.comA

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Sold by BNP Paribas Financial Markets

June 1, 2025 | marketbeat.com

Insider Selling: Lifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Sells 96,137 Shares of Stock

May 30, 2025 | marketbeat.com

Aron R. English Sells 150,419 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stock

May 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVM, LFCR, CRVS, and CADL Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.49 -0.09 (-3.49%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.50 +0.01 (+0.40%)

As of 04:00 AM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Candel Therapeutics NASDAQ:CADL

$5.03 +0.18 (+3.71%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$5.00 -0.03 (-0.50%)

As of 06/26/2025 07:58 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Corvus Pharmaceuticals NASDAQ:CRVS

$4.21 +0.09 (+2.18%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$4.15 -0.06 (-1.40%)

As of 06/26/2025 07:50 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Lifecore Biomedical NASDAQ:LFCR

$8.23 -0.11 (-1.32%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$8.15 -0.08 (-0.96%)

As of 04:28 AM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time